Comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from
meta-analysis of clinical trials and human genetics” | Science Translational Medicine news …

Introduction The independent and causal cardiovascular disease risk factor lipoprotein
(a)(Lp (a)) is elevated in> 1.5 billion individuals worldwide, but studies have prioritised …

Background The emergence of promising compounds to lower lipoprotein (a)[Lp (a)] has
increased the need for a precise characterisation and comparability assessment of Lp (a) …

Results The prevalence of Lp (a)≥ 30 mg/dl was 20.5% and 23.0%, and prevalence of Lp
(a)≥ 50 mg/dl was 13.3% and 15.2%, in men and women, respectively. An association of Lp …

Rationale & Objective Many adults with chronic kidney disease (CKD) and atherosclerotic
cardiovascular disease (ASCVD) have high lipoprotein (a) levels. It is unclear whether high …

Abstract Lipoprotein (a)(Lp (a)) is a highly proatherogenic lipid fraction that is genetically
determined and minimally responsive to lifestyle or behavior changes. Mendelian …

The present study was to explore the association between lipoprotein (a)[Lp (a)] and
colorectal cancer (CRC) among inpatients. This study included 2822 participants (393 cases …

Abstract Background Serum lipoprotein (a)[Lp (a)] is an independent risk factor for
atherosclerotic cardiovascular disease (ASCVD) in the general population, its association …

Abstract Purpose of Review Lipoprotein (a) levels are determined 80–90% by genetics and
differ by up to 1000-fold between individuals. This review discusses the most recent …

Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality
in both men and women with T1DM and T2DM. In patients with T1DM, intensive glycemic …